Dr. Danny Reinberg is the only Howard Hughes Medical Institute investigator in Florida
By Richard Westlund
Dr. Danny Reinberg hopes to attract more talented researchers to Sylvester.
ne of the world’s foremost biochemists is joining Sylvester Comprehensive Cancer Center at the Miller School, bringing decades of groundbreaking research in genetics, epigenetics and cellular processes. Danny Reinberg, Ph.D., a biochemistry and molecular mechanisms expert, is currently the only Howard Hughes Medical Institute Investigator in Florida — a prestigious designation that indicates the powerful impact of his studies. He is taking on the roles of associate director of faculty training and recruitment at Sylvester, and associate director of faculty training and recruitment and a distinguished professor at Miller School.
“Dr. Danny Reinberg is one of the most accomplished biomedical scientists in the world,” said Sylvester Director Stephen D. Nimer, M.D., the Oscar de la Renta Endowed Chair in Cancer Research and executive dean for research at the Miller School. “An icon in his field, he brings tremendous energy, expertise and commitment to Sylvester and the Department of Human Genetics that will further elevate our cancer research and its impact on our community. Dr. Reinberg is also committed to helping us bring the brightest and most diverse students and trainees to our institution and creating an environment of collaboration that will guide our junior faculty as well.”
Joining Sylvester after 17 years at New York University Langone School of Medicine, Dr. Reinberg is looking forward to the next chapter in his stellar career.
“I am excited about bringing my research to Miami and expanding my laboratory team,” he said. “As South Florida’s only National Cancer Institute-designated cancer center, Sylvester has a strong foundation in place for future scientific discoveries. One of my goals is to bring other outstanding scientists to Sylvester, attract more students and postdoctoral trainees from Latin America, the Caribbean and Europe, and build the pipeline of new cancer researchers.”